Canada Markets open in 7 hrs 27 mins

Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention

Panel to Feature Discussion About Creating a Winning Culture in the Biotech Industry

TORONTO, June 3, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company"), announced today that Executive Co-Chairman and Chief Executive Officer, Dr. Raza Bokhari, will be featured in the 2019 BIO International Convention's panel presentation, "Building a Winning Team for Biotech Business Success – Lessons You Can Learn from Industry Veterans and Former NFL Player Turned Broadcaster Solomon Wilcots," on June 4 in Philadelphia, PA.

FSD Pharma Inc. (CNW Group/FSD Pharma Inc.)

Moderated by Mr. Wilcots, the panel will feature an interactive discussion on how industry leaders in biotech create a culture committed to winning and why these approaches are applicable to fast-growing, emerging biotech companies today. Joining Dr. Bokhari will be Mei Mei Hu, CEO of United Neuroscience; Bill Newell, CEO of Sutro BioPharma; and Gil Van Bokkelen, Chairman and CEO of Athersys.

Details of the panel are as follows:

Panel:


Building a Winning Team for Biotech Business Success – Lessons You Can Learn from Industry Veterans and Former NFL Player Turned Broadcaster Solomon Wilcots

Date:


Tuesday, Jun 4, 2019

Time:


3:15 p.m. ET

Location:


107AB, Level 100, Pennsylvania Convention Center, Philadelphia, PA

 

About FSD Pharma
FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet that is licensed at its Ontario facility and expansion is currently underway.

FSD facilities sit on 70 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet by 2025.

FSD's wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its Sale for Medical Purposes license on April 18, 2019. FV Pharma's vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development. For additional information on the company, please visit our website at www.fsdpharma.com.

Forward-Looking Information
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on FSD Pharma's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Actual results and developments may differ materially from those contemplated by these. The forward-looking information contained in this press release is made as of the date hereof, and FSD Pharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE FSD Pharma Inc.


View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/03/c1734.html